2009
DOI: 10.1055/s-0029-1213924
|View full text |Cite
|
Sign up to set email alerts
|

Phase II Prüfung von Sagopilon, einem neuen Epothilon, als Zweitlinientherapie bei Patienten mit Stadium IIIB-IV NSCLC

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles